Sign in

CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Rapport Therapeutics, Inc.

Sign in to watch
Ticker
RAPP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
880724208
Phone
857-321-8020
Business address
99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
Former names
Rapport Therapeutics, Inc.
  1. 4 Planned sale Chief Executive Officer sold 8,220 shares at an average $39.83 ($327,398)
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Planned sale 10% owner sold 18,572 shares at $40.05 ($743,753)
  11. 4 Planned sale 10% owner sold 133,618 shares at $40.24 ($5,377,323)
  12. 4 Planned sale 10% owner sold 276,513 shares at an average $40.12 ($11,094,906)
  13. 4 Planned sale 10% owner sold 426,005 shares at $40.32 ($17,175,244)
  14. 4 Planned sale Chief Development Officer sold 20,225 shares at $39.99 ($808,844)
  15. 4 Planned sale Chief Development Officer sold 19,865 shares at an average $35.03 ($695,823)
  16. 4 Planned sale Chief Development Officer sold 360 shares at $34.90 ($12,564)
  17. 4 Planned sale Chief Operating Officer sold 10,000 shares at an average $28.19 ($281,857)
  18. 4 Planned sale Chief Development Officer sold 10,115 shares at $29.99 ($303,355)
  19. 4 Open-market sale Chief Operating Officer sold 2,014 shares at $28.93 ($58,265)
  20. 4 Planned sale Chief Executive Officer sold 10,916 shares at an average $29.35 ($320,373)

Page 2 of 6 · 120 filings